Oncology

Featured Article
Chemotherapy Drug Recalled
A Class II recall is active for a prescription chemotherapy drug used to treat cancer of the colon or rectum.
Self-Care Disability Decreases Likelihood of NSCLC Therapy for NH Patients
Researchers found that systemic cancer therapy for nursing home patients with advanced non-small cell lung cancer is even less likely when patients have limitations that interfere with self-care.
The Ideal Elective Surgery During a Pandemic
This article explains how David Silver, MD, chief of urology and director of the Prostate Center at Maimonides Medical Center, changed his treatment decisions amid the pandemic, and highlights the…

Newsfeed

Chemotherapy Drug Recalled
Self-Care Disability Decreases Likelihood of NSCLC Therapy for NH Patients
The Ideal Elective Surgery During a Pandemic
Reviewing the Recent FDA Approval of Venclexta for AML
Using Minimal Residual Disease to Improve Treatment Outcomes Among Patients With Cancer
Study Supports the Need for Real-World Evidence to Better Manage CLL Patients
Benefits of Dual Treatment for MCL
First-Line Ibrutinib Treatment Shows Long-Term Efficacy, High PFS and OS Rates in CLL
View More

Insights

The Ideal Elective Surgery During a Pandemic
This article explains how David Silver, MD, chief of urology and director of the Prostate Center at Maimonides Medical Center, changed his treatment decisions amid the pandemic, and highlights the use of the new CPT code for high intensity focused…
Reviewing the Recent FDA Approval of Venclexta for AML
Tony Lin, PharmD, senior scientific director, AbbVie US medical affairs, discusses the VIALE-A and VIALE-C trials, which helped determine the approval of Venclexta for acute myeloid leukemia, and highlights what this approval means for clinical…
Using Minimal Residual Disease to Improve Treatment Outcomes Among Patients With Cancer
“With more specific and accurate information about a patient’s disease status or how that patient is responding to treatment, doctors can have more robust conversations with their patients about treatment goals, treatment effectiveness, and future…
Study Supports the Need for Real-World Evidence to Better Manage CLL Patients
Anthony Mato, MD, Memorial Sloan Kettering Cancer Center, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with chronic lymphocytic leukemia (CLL) in the clinical practice setting, using the informCLL…
View More

Interactive Features

Examining Positive Results of Treatment for Patients With Endometrial Cancer
Sarah Temkin, MD, board-certified gynecologic oncologist, and Don Dizon, MD, oncologist specializing in women’s cancers, discuss an ongoing Phase III trial that examines the use of selinexor for the treatment of endometrial cancer, and highlight…
Positive Results Support Approval of Treatment for Patients With Multiple Myeloma
Saad Usmani, MD, discusses the recent approval of daratumumab subcutaneous formulation for patients with multiple myeloma, and explains the major benefits of this treatment for this patient population.
Breaking Down the Expanded Approval of a CLL Treatment
In this podcast, Andree Amelsberg, vice president of US Medical Affairs Oncology and Hematology at Janssen, and Danelle James, Imbruvica clinical science lead at Pharmacyclics LLC, an AbbVie company, discuss the recent expanded approval of Imbruvica…
Developing New Care Models Based on the Oncology Care Model
In this podcast, Charles Saunders, MD, CEO of Integra Connect, discusses how the four reporting periods of the Oncology Care Model can help develop new models of care, and provides best practices to help the health care industry progress faster and…
View More
Back to Top